Company
Major South Korean pharmaceutical company making drugs such as P-CAB stomach acid treatments, diabetes therapies, and botulinum toxin products.
Daewoong Pharmaceutical is building a sterile, automated microneedle plant at Daewoong Bio's Plant 3 and plans GMP certification by the first half of 2027. The site's first job is trial supply of DWRX5003, a semaglutide patch.
Reality
Emocog's route into Korean clinics is now a drugmaker's sales force. The three-year exclusive covers hospitals, clinics and public health centers nationwide, and the screening test that feeds the prescriptions goes with it.
Reality
The FDA is investigating whether GLP-1 drugs cause sudden vision loss, and the New Jersey filings number in the dozens. The market those drugs sell into is projected at $92 billion this year.
Reality
K-CAB added 402 Chinese hospitals in the first half and grew sales more than 30%. What holds its second place is NRDL coverage and a patent that outlasts Takeda's by 64 months.
Reality
Combined first-half research spending reached 562.8 billion won. Chong Kun Dang's 37% jump supplied nearly 40% of the group's increase, and the filings carry no profit lines to weigh it against.
Reality
The ring-shaped blood pressure monitor is already in 38 of Korea's 47 tertiary hospitals. The KOSDAQ listing asks investors to fund two more loss-making years before the thesis pays.
Reality